BioAdvance News

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

By WebmasterOctober 7, 2021November 1st, 2024No Comments

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

See more here

Previous PostPhrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance
Next PostAnnovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson's Disease

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostPhrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance

Next PostAnnovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson's Disease